OOIR: Observatory of International Research

Papers

(The TQCC of Annals of the Rheumatic Diseases is 0. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)

Article	Citations
Repeated false-negative tests delayed diagnosis of COVID-19 in a case with granulomatosis with polyangiitis under maintenance therapy with rituximab and concomitant influenza pneumonia	1535
Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumat	937
Response to: ‘Correspondence on ‘What comes after the lockdown? Clustering of ANCA-associated vasculitis: single-centre observation of a spatiotemporal pattern’’ by Hocevar et al	896
Time to treat the climate and nature crisis as one indivisible global health emergency	640
AB0738 EXPRESSION AND ROLE OF THE LNCRNA RP11-184M15.1 IN THE MYELOID COMPARTMENT DURING INFLAMMATION	545
AB1028 EFFECT OF RENIN-ANGIOTENSIN-SYSTEM INHIBITORS ON RENAL REMISSION IN LUPUS NEPHRITIS: A REAL-WORLD STUDY	390
POS1394 VITAMIN D SUPPLEMENTATION REDUCES IMMUNOGLOBULIN DEPOSITS IN THE BRAIN OF PRISTANE-INDUCED LUPUS MICE	372
POS0813 PREDICTORS OF RESPONSE TO bDMARDs AND tsDMARDs THERAPY: THE ROLE OF MUSCULOSKELETAL ULTRASOUND AND POTENTIAL NEW BIOMARKERS	353
OP0012 AN INVESTIGATION OF THE DIFFERENTIAL THERAPEUTIC EFFECTS OF ROMOSOZUMAB ON POSTMENOPAUSAL OSTEOPOROSIS PATIENTS WITH OR WITHOUT RHEUMATOID ARTHRITIS COMPLICATIONS: A CASE-CONTROL STUDY	334
OP0251 DURATION OF CLINICALLY MEANINGFUL ANALGESIC RESPONSE TO INTRA-ARTICULAR MM-II, A NOVEL SUSPENSION OF LARGE, EMPTY, MULTILAMELLAR LIPOSOMES, IN PATIENTS WITH PAINFUL KNEE OSTEOARTHRITIS: ANALYSI	323
AB1258 EFFECTIVENESS OF DUPILUMAB ON REFRACTORY CHRONIC RHINOSINUSITIS WITH NASAL POLYPS IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS: A CLINICAL AND CYTOLOGICAL STUDY	281
AB1320 DOPPLER ULTRASOUND IN GIANT CELL ARTERITIS: WHICH TERRITORIES SHOULD WE EXPLORE? A RETROSPECTIVE ANALYSIS OF A SINGLE CENTER EXPERIENCE	245
AB1365 SKELETAL METASTASES OF DIGESTIVE ORIGIN IN RHEUMATOLOGY: A DESCRIPTIVE STUDY OF 18 CASES	236
AB0847 KIDNEY INVOLVEMENT AND PROGRESSION IN PATIENTS WITH SYSTEMIC SCLEROSIS AND ISOLATED SJÖGREN’S SYNDROME	229
AB1323 ALL WALES GCA AUDIT 2023-A QUALITY IMPROVEMENT INITIATIVE TO IMPROVE GCA CARE ACROSS WALES	211
AB0372 PAIN SYNDROME, PHYSICAL ACTIVITY AND QUALITY OF LIFE IN WOMEN WITH OSTEOARTHRITIS AND SARCOPENIA	208
AB1272 MANAGING OF ANCA-ASSOCIATED VASCULITIS: ADHERENCE TO TREATMENT GUIDELINES AND EARLY MODIFICATIONS, ARE WE THERE YET?	199
AB1050 ANALYSIS OF FACTORS INFLUENCING THE NUMBER OF CHILDREN OF FEMALE SLE PATIENTS BY PATIENT’S QUESTIONNAIRE	188
POS0743 OPTIMIZING REFERRAL TO RHEUMATOLOGY – A NEW STRATEGY TO PREVENT REFERRAL OF PATIENTS WITH LOW LIKELIHOOD OF AN INFLAMMATORY RHEUMATIC DISEASE	187
AB1732 PROFILE OF MULTISYSTEM INFLAMMATORY SYNDROME (MIS-C) IN INFANTS DURING THE SECOND WAVE OF SARS-CoV-2 PANDEMIC: AN OBSERVATIONAL CROSS-SECTIONAL STUDY	165
AB1126 REBAMIPIDE ATTENUATES RENAL MANIFESTATIONS VIA ANTIOXIDANT EFFECTS ON PODOCYTES IN AN ANIMAL MODEL FOR SYSTEMIC LUPUS ERYTHEMATOSUS	164
OP0214 ASSOCIATIONS OF REMNANT CHOLESTEROL WITH ALL-CAUSE AND CAUSE-SPECIFIC THROMBOTIC RISK IN INDIVIDUALS WITH ANTIPHOSPHOLIPID SYNDROME	156
POS1107 IMMUNOGENICITY, REACTOGENICITY AND SAFETY OF 2 DOSES OF AN ADJUVANTED HERPES ZOSTER SUBUNIT VACCINE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A RANDOMIZED CLINICAL TRIAL	150
POS1001 INDUCED PLURIPOTENT STEM CELL-DERIVED MESENCHYMAL STEM CELLS ALLEVIATE SJÖGREN’S SYNDROME BY MODULATING THE MATURATION PROCESS OF SPLENIC B CELLS	148
POS1108 SUBCLINICAL ATHEROSCLEROSIS IS ASSOCIATED WITH FUTURE CARDIOVASCULAR EVENTS IN SYSTEMIC LUPUS ERYTHEMATOSUS PATIENTS AT APPARENT LOW RISK FOR CARDIOVASCULAR DISEASE: A LONGITUDINAL PROSPECTIVE	147

POS0389 LOW INCIDENCE OF LATE-ONSET GCA DURING THE FIRST YEAR IN PATIENTS WITH POLYMYALGIA RHEUMATICA — AN IMAGING-BASED STUDY	145
POS0916 DRUG SURVIVAL OF BIOLOGIC AND TARGETED SYNTHETIC DISEASE-MODIFYING ANTIRHEUMATIC THERAPIES IN PATIENTS WITH INFLAMMATORY ARTHRITIS: DATA FROM FIVE COUNTRIES OF LATIN AMERICA	144
AB1412 IMAGING TECHNIQUES IN ASSESSING THE MUSCULAR STATUS OF PATIENTS WITH CORONARY HEART DISEASE	142
POS0993 ELEVATED INTRACELLULAR IFN SIGNALING BY T AND B CELLS BUT UNALTERED B CELL DISTRIBUTION IS A CHARACTERISTIC OF ANTI-SSA POSITIVE ASYMPTOMATIC WOMEN AT-RISK FOR CONGENITAL HEART BLOCK	141
AB0661 TOFACITINIB PLUS IGURATIMOD IN RHEUMATOID ARTHRITIS-RELATED PROGRESSIVE FIBROSING INTERSTITIAL LUNG DISEASE: 13 CASES FROM A SINGLE CENTRE IN CHINA	141
AB1151 CIRCULATING CTHRC1 LEVELS ARE ASSOCIATED WITH DISEASE SEVERITY AND PREDICT SURVIVAL IN SYSTEMIC SCLEROSIS	137
OP0120 EFFECTIVENESS AND COST-EFFECTIVENESS OF PATIENT-INITIATED FOLLOW-UP SUPPORTED BY ASYNCHRONOUS TELEMONITORING IN SPONDYLOARTHRITIS (TeleSpA-STUDY): A PRAGMATIC MULTICENTRE RANDOMISED CONTROLLED	133
POS0443 PREVALENCE OF EARLY AXIAL SPONDYLOARTHRITIS IN THE Be-GIANT COHORT BASED ON THE ASAS CONSENSUS DEFINITION OF EARLY AXIAL SPONDYLOARTHRITIS	132
POS0878 INFERTILITY AND THE CHANCE OF SUCCESSFUL ASSISTED REPRODUCTION TREATMENTS IN CHILDBEARING WOMEN WITH RHEUMATIC DISEASES	131
AB0666 CYCLING VERSUS SWITCHING AFTER INEFFECTIVENESS OF FIRST TUMOR NECROSIS FACTOR INHIBITOR DURING FIRST YEAR OF THERAPY - DEMOGRAPHIC AND CLINICAL DIFFERENCES IN RHEUMATOID ARTHRITIS	130
AB1419 CLINICAL ANALYSIS OF FOUR CASES OF PACHYDERMOPERIOSTOSIS	124
POS0115 EOSINOPHILIC GIANT CELL ARTERITIS: A DIFFERENT SUBSET OF DISEASE?	122
POS0160-HPR IMPACT OF A SMARTPHONE DIGITAL THERAPEUTIC (DTx) APP WITH REAL-TIME FEEDBACK IN THE MANAGEMENT OF AXIAL SPONDYLOARTHRITIS (axSpA) THROUGH PHYSIOTHERAPY HOME-BASED EXERCISE PROGRAM: A PILOT	121
POS1377 REFINING AUTOANTIBODY PROFILES IN PATIENTS WITH RHEUMATOID ARTHRITIS – A SCANDINAVIAN STUDY ON 6900 SAMPLES	121
AB0445 EVALUATION OF SUBCLINICAL BOWEL INFLAMMATION USING FAECAL CALPROTECTIN LEVEL IN PATIENTS WITH PSORIATIC ARTHRITIS AND PSORIASIS – A PILOT STUDY	121
POS1258 STRATIFICATION OF SJÖGREN’S DISEASE, BASED ON SYMPTOMS, CLINICAL AND ROUTINE BIOLOGICAL DATA, IS SUPPORTED BY DISTINCT PATHOPHYSIOLOGICAL PATHWAYS	118
POS0344 PAROTID TRANSCRIPTOMIC NETWORKS ASSOCIATED WITH B CELL HYPERACTIVITY, AND VIRUS/IFN ACTIVITY ARE TARGETED BY LEFLUNOMIDE/HYDROXYCHLOROQUINE THERAPY IN SJÖGREN PATIENTS AND ARE CAPTURED BY A CI	118
POS0341 DECONVOLUTION OF TRANSCRIPTOMICS CHANGES IN DEUCRAVACITINIB-TREATED SUBJECTS REVEALS NOVEL MECHANISTIC EFFECTS OF TYK2 INHIBITION IN LUPUS	117
POS1117 1-YEAR FOLLOW-UP OUTCOME OF DIFFERENT TREATMENT REGIMENS FOR LUPUS NEPHRITIS	115
POS0532 DEUCRAVACITINIB, AN ORAL, ALLOSTERIC, TYROSINE KINASE 2 (TYK2) INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: PATIENT-REPORTED OUTCOMES IN A PHASE 2 TRIAL	112
AB0916 EFFECTIVENESS OF A PERSONALIZED PHYSICAL TRAINING PROGRAM ON DISEASE ACTIVITY AND AEROBIC CAPACITY IN axSpA: A RANDOMIZED CONTROLLED STUDY	112
POS1216 NIEMANN-PICK PROTEINS TYPE C2 DRIVES PROINFLAMMATORY PROPERTIES OF FIBROBLAST-LIKE SYNOVIOCYTES IN RHEUMATOID ARTHRITIS THROUGH MEDIATING CHOLESTEROL METABOLIC REPROGRAMMING	112
POS0061 INTERCEPTION OF THE DEVELOPMENT OF RHEUMATOID ARTHRITIS BY A 1-YEAR COURSE OF METHOTREXATE IN ACPA-NEGATIVE ARTHRALGIA PATIENTS AT INCREASED RISK FOR RHEUMATOID ARTHRITIS: 4 YEAR RESULTS OF TH	111
POS1220 MODULATING INFLAMMATION IN AN ADVANCED 3D MODEL OF RHEUMATOID ARTHRITIS SYNOVIAL TISSUE INCORPORATING FIBROBLASTS, ENDOTHELIAL CELLS AND MACROPHAGES	110
AB0462 ONE-YEAR RETENTION RATE OF IXEKIZUMAB IN PATIENTS WITH PSORIATIC ARTHRITIS AND AXIAL SPONDYLOARTHRITIS. DATA OF THE SPANISH BIOBADASER REGISTRY	109
POS0283 DISEASE - CHARACTERISTIC CHANGES CAN ALREADY BE FOUND IN INDIVIDUALS AT RISK OF SJÖGREN’S SYNDROME – RESULTS OF THE preSStige STUDY	108
AB0482 PREVALENCE AND SEVERITY OF MAFLD IN PSORIATIC DISEASE: ARE WE MISSING SOMETHING?	106
AB0251 CLINICAL FEATURES OF KOREAN PATIENTS WITH ANTI-SRP ANTIBODY-ASSOCIATED IMMUNE-MEDIATED NECROTIZING MYOPATHY	105
POS0118-PARE THE RAIISE SCHOOL PACK FOR TEACHERS SUPPORTING CHILDREN AND YOUNG PEOPLE WITH INVISIBLE ILLNESSES IN SCHOOL: A MULTI-STAKEHOLDER CO-CREATION PROCESS	104
AB0943 ASSESSING THE IMPACT OF SARCOPENIA IN AXIAL SPONDYLOARTHRITIS	103
POS0615 IS DMARD-FREE REMISSION IMPOSSIBLE FOR ALL RHEUMATOID ARTHRITIS PATIENTS OR ONLY FOR THOSE REQUIRING BIOLOGICALS?	103
POS1477-HPR UNDERSTANDING TREATMENT UTILISATION IN INDIVIDUALS WITH OSTEOARTHRITIS AND METABOLIC MULTIMORBIDITY: A CROSS-SECTIONAL STUDY	102
AB0255 DESCRIPTIVE ANALYSIS OF A COHORT OF PATIENTS WITH JUVENILE DERMATOMYOSITIS UNDER FOLLOW-UP IN THE ADULT RHEUMATOLOGY OFFICE	102
POS0866 LARGE-VESSEL INVOLVEMENT IN ANCA-ASSOCIATED VASCULITIS: A MULTICENTER CASE-CONTROL STUDY	98
POS0697 OPHTHALMIC MANIFESTATIONS IN TAKAYASU ARTERITIS PATIENTS: A CROSS-SECTIONAL MONOCENTRIC STUDY	96
POS1478-HPR ANALYSIS OF MEDICATION USAGE AND MONTHLY COSTS IN HOSPITALIZED PATIENTS WITH RHEUMATIC DISEASES: A RETROSPECTIVE OBSERVATIONAL STUDY	95
AB1285 ACUTE BRACHIAL PLEXITIS IN GIANT CELL ARTERITIS A CASE REPORT AND SYSTEMATIC REVIEW OF THE LITERATURE	95
POS0234 IMPACT OF PROPHYLACTIC TRIMETHOPRIM-SULFAMETHOXAZOLE ON THE INCIDENCE OF SERIOUS INFECTION IN PATIENTS WITH ANCA ASSOCIATED VASCULITIS: A MULTICENTER COHORT STUDY	93
AB1598-HPR MOTHERHOOD AND FAMILY PLANNING BELIEFS IN WOMEN WITH AUTOIMMUNE RHEUMATIC DISEASES	91
POS0226 GRANULOMATOSIS WITH POLYANGIITIS AND COURSE OF PREGNANCY - RESULTS FROM THE NATIONWIDE PREGNANCY REGISTER REVNATUS	89
AB0503 SELF-REPORTED CLINICAL AND PSYCHOLOGICAL FACTORS ASSOCIATED WITH ADHERENCE: RESULTS FROM THE BRAGGSS COHORT	86
AB1620-HPR CHANGE IN THE UTILITY OF ANTINUCLEAR ANTIBODIES (ANA) FOLLOWING THE IMPLEMENTATION OF ANALYTICAL REQUEST BASED ON PATIENT PROFILE	86
AB1294 EFFICACY AND SAFETY OF DISEASE-MODIFYING ANTI-RHEUMATIC DRUGS IN THE TREATMENT OF TAKAYASU ARTERITIS	86
AB1225 COMPARISON OF THE ACUTE EFFECTS OF INTRAVENOUS ILOPROST ON FINGER POWER DOPPLER ULTRASOUND IN SCLERODERMA PATIENTS IN TWO INFUSION 4 WEEKS APART	86
AB1618-HPR ENHANCING HERPES ZOSTER VACCINATION AMONG ADULT RHEUMATOLOGY PATIENTS ON JAK INHIBITORS IN KUWAIT: ASSESSING CURRENT UPTAKE AND IDENTIFYING IMPROVEMENT OPPORTUNITIES - A QUALITY IMPROVEMENT	85
POS1386 REGIONAL DIFFERENCES IN PATIENT DIAGNOSIS JOURNEY AND HEALTHCARE UTILIZATION. RESULTS FROM THE INTERNATIONAL MAP OF AXIAL SPONDYLOARTHRITIS (IMAS)	84
POS0449 GENE THERAPY WITH INTERFERENCE miRNAs AS A NEW ALTERNATIVE FOR DISCOID CUTANEOUS LUPUS (DLE)	84
AB1636-HPR SOCIAL MEDIA USE BY PHYSIOTHERAPISTS, OCCUPATIONAL THERAPISTS AND ALLIED HEALTHCARE PROFESSIONALS IN KAZAKHSTAN	81
POS0648 EFFICACY AND SAFETY OF LOW OR HIGH DOSE METHOTREXATE IN COMBINATION WITH ADALIMUMAB IN PATIENTS WITH ELDERLY-ONSET RHEUMATOID ARTHRITIS: RESULTS FROM THE RANDOMISED, CONTROLLED MIRACLE TRIAL	80
AB1233 ROLE OF HEMATOLOGICAL INDICES IN SYSTEMIC SCLEROSIS: USE AS A PREDICTOR OF SUBCLINICAL VASCULAR DAMAGE, CARDIOVASCULAR EVENTS AND DEATH	79

POS0349 SINGLE OSTEOCLAST RESORPTION ANALYSIS REVEALS AN INCREASED INTRINSIC OSTEOCLAST ACTIVITY IN RA PATIENTS	78
POS0307 CENTRAL SENSITIVITY SYNDROME AFFECTS THE TREATMENT SATISFACTION IN PATIENTS WITH RHEUMATOID ARTHRITIS	77
OP0037 A MULTICENTER, RANDOMIZED, PLACEBO-CONTROLLED, DOUBLE-BLIND, PHASE 3 STUDY OF SHR0302, A SELECTIVE JANUS KINASE 1 INHIBITOR, IN PATIENTS WITH ACTIVE RHEUMATOID ARTHRITIS AND INADEQUATE RESPONSE	77
AB0040 DIFFERENCIALLY EXPRESSED GENES IN PATIENTS WITH OSTEOARTHRITIS	77
POS1597-HPR ASSESSING THE USE OF VOICE COMMANDS IN THE CLINICAL SETTING	76
AB0771 FEMALE GENDER AND STEROID TREATMENT AS MAIN INFLUENCING FACTORS IN THE PERCEPTION OF QUALITY OF LIFE IN ANCA-ASSOCIATED VASCULITIS: FINAL RESULTS FROM THE ITALIAN VERSION OF ANCA-ASSOCIATED VAS	76
AB0070 PIM KYNASES AS POSSIBLE THERAPEUTIC TARGETS IN INFLAMMARORY ARTHRITIDES	75
AB0112 IT IS SAFE AND EFFECTIVE TO USE HUMAN CXCL5 TO TREAT MURINE LUPUS	74
AB0082 AGE-RELATED GENES USP2 AND ARG2 ARE INVOLVED IN THE REDUCTION OF IMMUNE CELL INFILTRATION IN ELDERLY PATIENTS WITH RHEUMATOID ARTHRITIS	74
AB0216 INHIBITION OF RADIOGRAPHIC JOINT DAMAGE BY JAK INHIBITORS IN PATIENTS WITH DESTRUCTIVE RHEUMATOID ARTHRITIS WITH EXTENSIVE BONE MARROW EDEMA IN HAND	72
AB0400 THE PATTERN OF INTERLEUKIN-6 INHIBITORS VERSUS OTHER BIOLOGIC DRUG USE IN PATIENTS WITH RHEUMATOID ARTHRITIS IN WALES, UK: A REAL-WORLD STUDY USING ELECTRONIC HEALTH RECORDS	72
AB0349 ENDOCRINE DYSFUNCTION IN PATIENTS WITH RHEUMATOID ARTHRITIS AND THEIR RELATIONSHIP TO DISEASE SEVERITY	72
AB1148 PATIENT AND PHYSICIAN GLOBAL ASSESSMENT OF PSORIATIC ARTHRITIS APPEAR MORE IN AGREEMENT IN ARAB COUNTRIES THAN PREVIOUSLY REPORTED ELSEWHERE – AN INTERNATIONAL STUDY UNDER THE AEGIS OF ARLAR	71
AB0406 EFFICACY OF TNF-ALPHA INHIBITORS IN MANAGEMENT OF IMMUNE CHECKPOINT INHIBITOR RELATED ARTHRITIS	71
AB0675 AVASCULAR NECROSIS IN A COHORT OF SLE PATIENTS IN AN AFRICAN CONTEXT	71
AB0174 EXPLORING A POTENTIAL ANTI-TUMOR IMMUNE MICROENVIRONMENT IN GIANT CELL ARTERITIS	70
AB0693 IN-OFFICE LACRIMAL BIOMARKERS IN PRIMARY SJÖGREN'S SYNDROME	70
AB0763 CHARACTERISTICS OF RELAPSES IN EOSINOPHILIC GRANULOMATOSIS WITH POLYANGIITIS. A SINGLE CENTRE EXPERIENCE	70
AB0685 DESCRIPTIVE STUDY OF A COHORT OF PATIENTS WITH NEUROPSYCHIATRIC MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS IN A TERTIARY HOSPITAL	70
AB0677 CUT OFF POINT OF NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A MARKER OF DISEASE ACTIVITY IN SYSTEMIC LUPUS ERYTHEMATOSUS AT HAJ ALSAFFE HOSPITAL LUPUS CLINIC FROM JUNE 2021 TO SEPTEMBER 2021	69
AB0297 FOOT AND ANKLE INVOLVEMENT IN RHEUMATOID ARTHRITIS IS ASSOCIATED WITH DISEASE ACTIVITY AND LESS INTENSIVE TREATMENT	69
AB0180 PAIN SENSITISATION IN FIBROMYALGIA. THE CROSS-SECTIONAL ASSOCIATIONS BETWEEN MEASURES OF QUANTITATIVE SENSORY TESTING AND FIBROMYALGIA SEVERITY	69
AB1339 EFFICACY AND SAFETY OF THE SARS-CoV-2 VACCINE IN PATIENTS WITH RHEUMATOID ARTHRITIS	69
AB0783 RISK FACTORS IN HENOCH-SCHӦNLEIN PURPURA NEPHRITIS	69
AB0819 CLINICAL AND IMMUNOLOGICAL PROFILES OF PATIENTS WITH ANTI-SYNTHETASE SYNDROME: A RETROSPECTIVE COHORT STUDY FROM A TERTIARY CENTRE	68
AB0846 EFFICACY OF RITUXIMAB IN IDIOPATHIC INFLAMMATORY MYOPATHIES. EXPERIENCE ON 36 PATIENTS FROM A PROSPECTIVE MONOCENTRIC COHORT	68
AB1047 COMORBIDITY WITH FIBROMYALGIA IS ASSOCIATED WITH INCREASED JOINT SWELLING, HIGH DISEASE ACTIVITY AND REDUCED PRODUCTIVITY IN THAI PATIENTS WITH SPONDYLOARTHRITIS	67
AB1098 DEUCRAVACITINIB IN PLAQUE PSORIASIS: 2-YEAR LABORATORY RESULTS FROM THE PHASE 3 POETYK PSO PROGRAM	67
AB1595 HOW DO WE PREVENT THE DEVELOPMENT OF MULTIMORBIDITY IN PEOPLE WITH INFLAMMATORY RHEUMATOLOGICAL DISORDERS: A QUALITATIVE INVESTIGATION	67
AB0591 COVID-19 VACCINE SAFETY DURING PREGNANCY IN WOMEN WITH SYSTEMIC LUPUS ERYTHEMATOSUS	67
AB0964 THERAPEUTIC DRUG MONITORING OF INFLIXIMAB IN INFLAMMATORY RHEUMATIC DISEASES: REAL-LIFE DATA IN A COHORT OF PATIENTS	66
AB0667 CHARACTERIZING ULTRASOUND-PROVEN ENTHESITIS IN SYSTEMIC LUPUS ERYTHEMATOSUS: PREVALENCE AND IDENTIFICATION OF DISEASE SUBSET WITH LESS FREQUENT RENAL INVOLVEMENT	65
AB1294 SAFETY OF COVID-19 VACCINES AND HEALTH CARE UTILIZATION FOLLOWING VACCINATION AMONG ADULTS WITH RHEUMATOID ARTHRITIS – A POPULATION-BASED SELF-CONTROLLED CASE SERIES ANALYSIS	64
AB0840 ACUTE VASCULAR EFFECTS OF INTRAVENOUS ILOPROST IN SCLERODERMA PATIENTS CAN BE DETECTED BY POWER DOPPLER EXAMINATION OF THE FINGER SUBCUTANEOUS TISSUE	63
AB1410 ASSOCIATION BETWEEN MUSCLE MASS PERCENTAGE WITH PAIN AND DISABILITY IN PATIENTS WITH NON-SPECIFIC CHRONIC LOW BACK PAIN: THE BACKFIT PROJECT	62
AB1436 BIOLOGIC THERAPY IN JUVENILE IDIOPATHIC ARTHRITIS TUNISIAN PATIENTS	61
AB1217 COMORBIDITIES DURING GONARTHROSIS	60
AB1694 IN VIVO MEASUREMENT OF POTENT AND DURABLE HUMAN ADIPOSE 11Β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 INHIBITION BY SPI-62	60
AB1054 SPONDYLOARTHRITIS IN FIRST DEGREE RELATIVES OF ANKYLOSING SPONDYLITIS PATIENTS	60
AB1351 FREQUENCY OF VACCINE-RELATED ADVERSE EVENTS IN PATIENTS WITH RHEUMATIC DISEASE	60
AB1291 COVID-19 AND CRYOGLOBULINEMIC VASCULITIS.LONG-TERM SURVEY STUDY ON THE IMPACT OF PANDEMIC AND VACCINATION ON A LARGE PATIENT'S POPULATION	57
AB1285 MODELING OF ANTIBODY RESPONSE TO COVID-19 VACCINATIONS IN PATIENTS WITH RHEUMATOID ARTHRITIS	57
POS1406 THE EFFECTS AND MOLECULAR MECHANISMS OF TRAF5 ON PULMONARY ARTERY ENDOTHELIAL CELLS IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS ASSOCIATED PULMONARY ARTERIAL HYPERTENSION	57
AB1729-PARE BEING “THE HEALTHY ONE”: THE HARD LIVING WITH A SICK BROTHER/SISTER	57
OP0180-HPR DOES FOLLOW-UP REALLY MATTER? A MIXED METHODS STUDY EXPLORING PATIENTS' PERSPECTIVES ON FOLLOW-UP SUPPORT IN REHABILITATION ACROSS LEVELS OF CARE	56
AB1709 AWARENESS OF EDUCATIONAL AND RESEARCH OFFERINGS OF EULAR AND EMEUNET AMONG YOUNG RHEUMATOLOGISTS WORKING IN TURKEY	56
POS1437 INTERSTITIAL ANCA-ASSOCIATED VASCULITIS ASSOCIATES WITH SEVERE KIDNEY INJURY INDEPENDENT OF GLOMERULONEPHRITIS	56
AB1487 EFFECTIVENESS OF RITUXIMAB IN IGG4-RELATED DISEASE. MULTICENTRE STUDY AND LITERATURE REVIEW	56
OP0123 AUTOANTIBODIES TO JOINT-RELATED PROTEINS PREDICT REMISSION IN NEW ONSET RA WITH HIGH SPECIFICITY	56
POS1460 MAJOR SALIVARY GLAND ULTRASOUND AND ELASTOGRAPHY FOR ASSESSMENT OF DISEASE ACTIVITY IN PATIENTS OF PRIMARY SJÖGREN'S SYNDROME	56
OP0200 ORAL DELIVERY OF DELTA-9-TETRAHYDROCANNABINOL PROVIDES SYMPTOM AND DISEASE MODIFICATION USING TWO MODELS OF KNEE OSTEOARTHRITIS	55
OP0209 IMPACT OF CHRONIC INFLAMMATION AND COLLAGEN IV FRAGMENT CANSTATIN ON RHEUMATOID ARTHRITIS SYNOVIAL FIBROBLASTS AND ENDOTHELIAL CELL INTERACTIONS IN VITRO AND IN VIVO	54
OP0243 PROTON PUMP INHIBITOR USE IS ASSOCIATED WITH IMPAIRED BONE MINERAL DENSITY BUT NOT BONE MICROARCHITECTURE IN PATIENTS WITH INFLAMMATORY RHEUMATIC AND MUSCULOSKELETAL DISEASES TAKING GLUCOCORTIC	52
OP0110 SINGLE CELL RNA-SEQ DISSECTION OF THE SYNOVIAL FLUID IN PSORIATIC ARTHRITIS PATIENTS IDENTIFIES MYELOID CELL SUBSETS RELATED TO TREATMENT RESPONSE WITH BDMARDS	52
POS0165 DETERMINATION OF DISTINCT PHENOTYPES OF PRIMARY SJÖGREN'S DISEASE USING CLUSTER ANALYSIS BASED ON CLINICAL AND BIOLOGICAL MANIFESTATIONS: DATA FROM 458 PATIENTS FROM THE PARIS SACLAY SJÖGREN'S	52
POS0128 TEN-YEAR ALL-CAUSE MORTALITY AND RISK FACTORS FOR DEATH IN A LARGE PROSPECTIVE REGISTRY COHORT OF IDIOPATHIC INFLAMMATORY MYOSITIS IN CHINA	52
POS0215 CLASSIC VERSUS ATYPICAL POLYMYALGIA RHEUMATICA: TWO SIDES OF THE SAME COIN OR MISCLASSIFICATION?	52
POS0042 HIGH-THROUGHPUT TRANSCRIPTOMIC PROFILING OF PERIPHERAL BLOOD MONONUCLEAR CELLS IN AXIAL SPONDYLOARTHRITIS PATIENTS REVEALS CO-EXPRESSED GENE MODULES ASSOCIATED WITH RADIOGRAPHIC DAMAGE	51
POS0429 THE COMPLEMENT SYSTEM AND RESPONSE TO TNF INHIBITION IN PATIENTS WITH RADIOGRAPHIC AXIAL SPONDYLOARTHRITIS. POST HOC ANALYSIS FROM CONSUL, A LONGITUDINAL MULTI-CENTER RCT COHORT OF R-AXSPA-PAT	51
POS0841 EFFECTIVENESS AND SAFETY OF UPADACITINIB IN PATIENTS WITH RHEUMATOID ARTHRITIS AND PRIOR TNF-THERAPY IN GERMANY. FINAL RESULTS FROM A POST-MARKETING OBSERVATIONAL STUDY	51
POS0253 FACTORS ASSOCIATED WITH TREATMENT PATHWAYS IN EARLY AXIAL SPONDYLOARTHRITIS: A MULTISTATE ANALYSIS OF THE 10-YEAR FOLLOW-UP OF THE DESIR COHORT	51
POS1369 CHANGES IN PAIN AND REACHING THE PATIENT ACCEPTABLE SYMPTOM STATE IN HAND OSTEOARTHRITIS OVER 4 YEARS	51
POS0919 [18F] POSITRON EMISSION COMPUTED TOMOGRAPHY ([18F] FDG PET/CT) IS ABLE TO PREDICT ULTRASOUND-DEFINED REMISSION IN RHEUMATOID ARTHRITIS	50
POS0650 FACING THE ISSUES OF CHANGE IN ENTRY VISIT DIAGNOSIS AND LOST OF FOLLOW-UP OVER TIME IN INCEPTION COHORTS: DATA FROM THE AXIAL SPONDYLARTHRITIS (AxSpA) DESIR COHORT	50
POS0935 THE COURSE OF CYTOKINE AND CHEMOKINE GENE EXPRESSION IN CLINICALLY SUSPECT ARTHRALGIA PATIENTS DURING PROGRESSION TO INFLAMMATORY ARTHRITIS	50
POS1010 MACROPHAGE EXTRACELLULAR TRAPS PROMOTE FIBROBLAST-LIKE SYNOVIOCYTES PROLIFERATION AND PROINFLAMMATORY CYTOKINE IN RHEUMATOID ARTHRITIS	49
POS1093 WHO ARE THE PATIENTS WITH INFLAMMATORY RHEUMATIC DISEASE IN NEED TO SPECIALISED MULTIDISCIPLINARY REHABILITATION?	48
POS0905 AXILLARY ARTERIES ULTRASOUND IN THE DIAGNOSIS OF GIANT CELL ARTERITIS WITH PREDOMINANTLY CRANIAL SYMPTOMS	48
POS1131 SECRETAGOGUE EFFECT OF PDE4 INHIBITOR APREMILAST ON HUMAN SALIVARY GLAND ORGANOIDS OBTAINED FROM PRIMARY SJÖGREN'S SYNDROME PATIENTS	47
POS1110 PATIENT CLUSTERS IDENTIFIED BY MACHINE LEARNING: DATA FROM A POOLED ANALYSIS OF PHASE-3 TRIALS OF SECUKINUMAB IN PSORIATIC ARTHRITIS, ANKYLOSING SPONDYLITIS AND PSORIATIC ARTHRITIS WITH AXIAL	47
POS1152 ATTAINMENT OF EULAR/ERA-EDTA TREATMENT TARGETS IN THE FIRST YEAR IN LUPUS NEPHRITIS: A MULTICENTER OBSERVATIONAL STUDY	47
POS1076 ARE DISEASE-MODIFYING ANTIRHEUMATIC DRUGS FOR RHEUMATOID ARTHRITIS ASSOCIATED WITH A LOWER RISK OF DEMENTIA? A SYSTEMATIC REVIEW WITH META-ANALYSIS	47
POS0913 LOW ADDITIVE VALUE OF A REPEAT MRI EXAMINATION OF THE SACROILIAC JOINTS WHEN THE FIRST MRI IS INCONCLUSIVE	47
AB0131 ASSOCIATION OF CYTOKINE AND CLINICAL EVALUATION BASED ON ULTRASOUND OF SALIVARY GLAND GRADE CLASSIFICATION IN PATIENTS WITH EARLY PRIMARY SJÖGREN'S SYNDROME	46
AB0110 FEASIBILITY OF AN IL-17A ASSAY IN PATIENTS WITH ACTIVE AXIAL SPONDYLOARTHRITIS	46
POS1481 INFORMING TRIAL MEASUREMENT IN SYSTEMIC LUPUS ERYTHEMATOSUS: FREQUENCY OF DOMAIN-SPECIFIC DISEASE ACTIVITY IN A MULTI-NATIONAL OBSERVATIONAL COHORT	45
POS1468 A HIGH GENETIC RISK OF SLE IS ASSOCIATED WITH AN INCREASED RISK OF MYOCARDIAL INFARCTION AND IMPAIRED KIDNEY FUNCTION; A COMBINED OBSERVATIONAL AND MENDELIAN RANDOMIZATION STUDY	45
AB0359 SALIVARY ULTRASONOGRAPHY AND HISTOPATHOLOGIC EVALUATION OF SECONDARY SJÖGREN'S SYNDROME IN RHEUMATOID ARTHRITIS PATIENTS	45
AB0038 HINDLIMB SUSPENSION INDUCES KNEE MALALIGNMENTS WITH PATELLOFEMORAL OSTEOARTHRITIS IN GROWING RATS	44
POS1262 ULTRASONOGRPHIC EVALUATION OF SALIVARY GLANDS IN PATIENTS WITH SYSTEMIC SCLEROSIS	44

AB0732 CELLULAR AND MOLECULAR HALLMARKS OF EARLY METHOTREXATE RESPONSE IN RA	43
AB1649-PARE BARRIERS TO DIAGNOSIS, TREATMENT, AND CARE FOR IgG4-RELATED DISEASE: DATA FROM A LARGE COHORT OF ITALIAN PATIENTS	43
POS0385 ORAL SYSTEMIC ENZYME COMBINATION ALLEVIATES SYSTEMIC INFLAMMATION, CARTILAGE DEGRADATION, AND PAIN IN KNEE OSTEOARTHRITIS–A PROOF-OF-MECHANISM, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STU	43
POS0714 MYOCARDITIS AND MAJOR ADVERSE CARDIOVASCULAR EVENTS (MACE) IN PATIENTS WITH MELANOMA RECEIVING IMMUNE CHECKPOINT INHIBITORS	43
POS1035 FORCED VITAL CAPACITY TRAJECTORIES AND RISK OF LUNG TRANSPLANT AND ILD-RELATED MORTALITY AMONG PATIENTS WITH RHEUMATOID ARTHRITIS-ASSOCIATED INTERSTITIAL LUNG DISEASE	42
AB0393 MUSCULOSKELETAL MANIFESTATIONS IN PATIENTS DIAGNOSED WITH MARFAN SYNDROME	42
AB1016 SERUM CXCL-13 LEVELS ARE ASSOCIATED WITH ACTIVE NEUROLOGICAL INVOLVEMENT IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	42
AB0313 SECONDARY PREVENTION OF OSTEOPOROSIS: CLINICAL AND FUNCTIONAL PROFILE OF ELDERLY PATIENTS WITH HIP FRACTURE	42
AB0394 COMORBIDITIES IN 40.643 PSORIATIC ARTHRITIS PATIENTS ACCORDING TO GENDER: RESULTS FROM E.PULSE, THE NATIONWIDE HEALTH DATA	41
AB1535 A PROFILE OF SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASE-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION (SARD-PAH) FROM WESTERN INDIA: A SINGLE CENTRE RETROSPECTIVE STUDY	41
POS0594 NEW INSIGHTS INTO EARLY AND ESTABLISHED RHEUMATOID ARTHRITIS SUBTYPES THROUGH SEROLOGIC BIOMARKER PROFILING – RESULTS FROM THE SCANDRA PROJECT	41
AB1553-HPR BASELINE CHARACTERISTICS OF PATIENTS WITH SLE ACROSS 5 REGISTRIES – THE LUPUSNET FEDERATED DATA NETWORK	40
AB0857 ASSOCIATIONS AMONG PATIENT EMPOWERMENT, PATIENT ENGAGEMENT, PATIENT ACTIVATION AND CLINICAL MANIFESTATIONS IN PRIMARY SJÖGREN’S SYNDROME	40
AB1089 CORRELATION OF AUTOANTIBODIES AND PERICARDITIS IN SLE PATIENTS	40
OP0057 EVALUATION OF SYSTEMIC SCLEROSIS PRIMARY HEART INVOLVEMENT IN THE EUROPEAN SCLERODERMA TRIALS AND RESEARCH (EUSTAR) COHORT	39
AB0183 CARDIAC EFFECTS OF THE ARTHRITIS/HEART FAILURE COMORBIDITY	39
AB1134 SERUM ADVANCED GLYCATION END-PRODUCTS AND THEIR SOLUBLE RECEPTOR AS POTENTIAL NEW BIOMARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS	39
POS0959 IMPACT OF INITIATION OF TARGETED THERAPY ON THE USE OF ASSOCIATED TREATMENTS AND HEALTHCARE CONSUMPTION IN PSORIATIC ARTHRITIS: A COHORT STUDY OF 9,793 PATIENTS FROM THE FRENCH HEALTH INSURANC	39
AB0085 PRE-EXPOSURE PROPHYLAXIS OF SARS-COV-2 INFECTION AND SEVERE COVID-19 WITH TIXAGEVIMAB AND CILGAVIMAB (EVUSHELD) IN RHEUMATOLOGIC PATIENTS TREATED WITH RITUXIMAB AT RISK OF SEVERE COVID-19: EFFI	38
AB0073 ANTIBODY RESPONSE AND COVID-19 DISEASE AFTER SARS-CoV-2 VACCINATION IN PATIENTS WITH IMMUNE-MEDIATED INFLAMMATORY DISEASES RECEIVING BIOLOGICAL TREATMENT	38
AB0160 THE USE OF IL-6 INHIBITORS IN PATIENTS WITH POLYMYALGIA RHEUMATICA RECEIVING GLUCOCORTICOID THERAPY: A SYSTEMATIC REVIEW AND META-ANALYSIS	38
AB0102 DIFFERENTIAL EXPRESSION OF ORTHOLOGUE GENES INVOLVED IN GLYCINE AND PYRUVATE METABOLISM CHARACTERIZE THE GUT MICROBIOME META-TRANSCRIPTOME OF SUBJECTS WITH ASYMPTOMATIC HYPERURICEMIA AND GOUT	38
POS1158 ASSESSMENT OF MYOSITIS SPECIFIC ANTIBODIES IN A PRIMARY ARTHRITIS COHORT: SINGLE CENTRE PROSPECTIVE STUDY	37
POS0007 Reduced Follicular Helper T cells in Peripheral Blood Marks a Distinct Feature of Retroperitoneal Fibrosis	37
AB0032 ASSESSMENT OF AUTONOMIC DYSFUNCTION AND ITS RELATIONS WITH CLINICAL PARAMETERS IN FAMILIAL MEDITERRANEAN FEVER (FMF)	37
ABS0292 CATASTROPHIC ANTIPHOSPHOLIPID SYNDROME: CLINICAL CHARACTERISTICS AND OUTCOMES. FIVE-YEAR EXPERIENCE	37
POS1387 DYSREGULATED GENES AND IMMUNE CELL SHIFTS IN OSTEOARTHRITIS HIGHLIGHTING M0 MACROPHAGES, MMP9, AND MAST CELL ACTIVITY	37
POS0634 ASSOCIATION OF RADIOLOGICAL FINDINGS OF THE HAND WITH HAND FUNCTION AND AUTOANTIBODIES IN PATIENTS WITH SYSTEMIC SCLEROSIS	37
POS1311 VASCULAR EFFECTS OF ACHIEVING LOW DISEASE ACTIVITY IN AXIAL SPONDYLARTHRITIS - A 2-YEAR PROSPECTIVE COHORT STUDY	37
ABS1158 ISOLATED ANTI-U1-RNP ANTIBODY DETECTED VIA PARTICLE-BASED MULTI-ANALYTE TECHNOLOGY (PMAT): CORRELATION OF TITRE INTENSITY WITH CONNECTIVE TISSUE DISEASES	37
ABS0750 FIRST USE OF NOVEL BCMA AND CD19 NANOBODY-BASED COMPOUND CAR-T THERAPY TO TARGET B-CELLS AND PLASMA CELLS IN PRECLINICAL STUDY OF AUTOIMMUNE DISEASES	36
ABS0462 REAL-WORLD OUTCOMES OF BARICITINIB MONOTHERAPY VERSUS csDMARD COMBINATION THERAPY IN RHEUMATOID ARTHRITIS: A SINGLE-CENTER RETROSPECTIVE ANALYSIS OF EFFICACY, SAFETY, AND DRUG RETENTION	36
ABS0950 ARTIFICIAL INTELLIGENCE ANALYSIS OF HRCT IMAGES REFLECTS PULMONARY INVOLVEMENT IN SYSTEMIC SCLEROSIS INTERSTITIAL LUNG DISEASE	36
POS1433 N-ACETYL-SERYL-ASPARTYL-LYSYL-PROLINE (AcSDKP) IN RHEUMATOID ARTHRITIS: A NOVEL BIOMARKER FOR DISEASE ACTIVITY AND THERAPEUTIC MONITORING	36
ABS0368 SERUM FERRITIN AS A SPECIFIC BIOMARKER OF ANTI-MDA5-ILD: A MULTICENTER, CASE-CONTROL STUDY IN OBSERVATIONAL AND VALIDATION DATASETS	36
ABS0887 VASCULOPATHY RATHER THAN SKIN FIBROSIS AS A PREDICTOR OF HAND FUNCTION WORSENING IN SYSTEMIC SCLEROSIS PATIENTS	36
POS0953 VASCULAR DAMAGE IS LESS PRESENT IN AN EARLY INCEPTION COHORT IN TAKAYASU'S ARTERITIS	36
ABS0082 IDENTIFICATION OF CORONARY MORPHOLOGICAL DAMAGE IN PATIENTS WITH CHRONIC INFLAMMATORY ARTHROPATHIES	36
ABS1003 ARE MYOSITIS ANTIBODIES MORE COMMON THAN WE KNOW – VERY HIGH PREVALENCE OF ANTI-HMGCR ANTIBODY IN A SINGLE-CENTRE UK COHORT	36
OP0275 POTENTIAL DRUG TARGETS FOR CHRONIC WIDESPREAD PAIN: A PROTEOME-WIDE MENDELIAN RANDOMIZATION AND DRUG REPURPOSING ANALYSIS	36
ABS1173-HPR EVALUATION OF A PHARMACIST-LED MEDICATION ADHERENCE CLINIC FOR RHEUMATOLOGY PATIENTS PRESCRIBED DMARDS	35
POS0695 SHIFT TOWARDS IgA EXPRESSION AND ABERRANT B CELL RECEPTOR SIGNALING RESPONSES IN DOUBLE NEGATIVE B CELLS FROM PATIENTS WITH PERIPHERAL SPONDYLOARTHRITIS	35
POS0985 CROSS CULTURAL VALIDATION OF WORK PRODUCTIVITY AND ACTIVITY IMPAIRMENT QUESTIONNAIRE IN LUPUS PATIENTS FROM LATIN AMERICA	35
POS1038 HIGH PREVALENCE OF INFLAMMATORY PsA-SPECIFIC FINDINGS IN PATIENTS WITH LONG-STANDING PSORIASIS BUT NO MUSCULOSKELETAL SYMPTOMS	35
POS1091 Development and Validation of ‘Rheumatic ‘ - A Digital Symptom Checker for Confirmation and Prediction of Rheumatic Diseases: A Large-Scale Prospective Study	34
POS0813 CAR T-CELL THERAPY IN SLE: A SYSTEMATIC/SCOPING REVIEW	34
POS1511-HPR PHYSICAL FITNESS AND FUNCTIONAL CAPACITY IN CHILDREN AND ADOLESCENTS WITH JUVENILE DERMATOMYOSITIS	34
POS1334 ACHIEVEMENT OF PROTEINURIA TARGETS =0.4 g/g IN LUPUS NEPHRITIS: A POST HOC ANALYSIS OF THE AURORA 1 STUDY OF VOCLOSPORIN	34
ABS1200-HPR A MULTICENTRIC CROSS SECTIONAL STUDY EVALUATING THE BONE HEALTH IN YOUNG PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS	34
ABS0439 PATH TO DIAGNOSIS IN FAMILIAL MEDITERRANEAN FEVER (FMF)	34
OP0333 INITIAL THERAPY IN SYSTEMIC SCLEROSIS-ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IMPROVES OUTCOMES ACROSS HAEMODYNAMIC THRESHOLDS AND RISK STRATIFICATION: INSIGHTS FROM THE EUSTAR DATABASE	34
POS0228 PROTEIN PROFILING TO IDENTIFY INFLAMMATORY MARKERS ASSOCIATED WITH FERTILITY IN RA; AN EXPLORATORY STUDY	33
POS1216 EFFECT OF GENDER AND FOLLOW-UP TIME IN DAMAGE ACCRUAL: DATA FROM A LATIN AMERICA LUPUS COHORT	33
OP0215 SPATIAL TRANSCRIPTOMICS OF SKIN BIOPSIES FROM VERY EARLY SYSTEMIC SCLEROSIS UNVEILS EARLY DRIVERS OF SKIN FIBROSIS WITHIN THE EPIDERMIS	33
OP0372-PARE Beyond the Doctor's Office: The School and Workplace Needs of Young People Living with Rheumatic Disease	33
ABS0931 SLEEP QUALITY IN SYSTEMIC LUPUS ERYTHEMATOSUS: COMPARISON OF OBJECTIVE AND SUBJECTIVE SLEEP ASSESSMENT METHODS	33
POS0878 A PATIENT WITH MENTAL HEALTH DISORDER IN CONSULTATION: WHAT ARE THE ATTITUDES OF RHEUMATOLOGISTS	33
POS1458-HPR EFFECTIVENESS OF A BIOPSYCHOSOCIAL-BASED EXERCISE APPROACH ON PATIENT OUTCOMES IN PRIMARY SJÖGREN'S SYNDROME: A PRELIMINARY RANDOMIZED CONTROLLED TRIAL	33
ABS0542 PARAPROTEINEMIAS IN SJÖGREN'S DISEASE: ISOLATED MONOCLONAL GAMMOPATHY AND CRYOGLOBULINEMIA DEFINE TWO DISTINCT DISEASE PHENOTYPES	32
POS0721 INTERPRETATION OF ANTI-NUCLEAR ANTIBODY INDIRECT IMMUNOFLUORESCENCE PATTERNS USING ARTIFICIAL INTELLIGENCE	32
ABS0060 UNDERSTANDING DRIVERS OF LUPUS PATHOGENESIS THROUGH COMPARISON OF PRECLINICAL MODELS	32
ABS0343 SUBCUTANEOUS ULTRA-LOW DOSE RITUXIMAB VERSUS INTRAVENOUS ULTRA-LOW DOSE RITUXIMAB IN PATIENTS WITH RHEUMATOID ARTHRITIS: A RANDOMISED CONTROLLED NON-INFERIORITY TRIAL	32
POS0704 LIPIDOMICS AND INFLAMMATION FOLLOWING DISEASE ONSET IN NEWLY DIAGNOSED RHEUMATOID ARTHRITIS: INSIGHTS FROM THE DESIGNA (DIETARY SIGNATURES IN ARTHRITIS) STUDY	32
ABS0357 EVALUATION OF THE UTILITY OF PHASE ANGLE IN THE DIAGNOSIS OF RHEUMATOID SARCOPENIA	32
POS1066 AN ALTERED IMMUNOMETABOLIC PROFILE CHARACTERIZES B CELLS OF PATIENTS WITH OLIGOARTICULAR- AND POLYARTICULAR- JUVENILE IDIOPATHIC ARTHRITIS	32
ABS0378 PROGRESSIVE OSSIFYING FIBRODYSPLASIA AS A VARIANT OF AXIAL SPONDYLOARTHRITIS WITH JUVENILE ONSET	32
ABS0310 IMPACT OF ANTI-CITRULLINATED PROTEIN ANTIBODIES ON TNF INHIBITOR AND JAK INHIBITOR PRESCRIPTIONS IN RHEUMATOID ARTHRITIS: CROSS-SECTIONAL STUDIES FROM THE ART AND MAJIK REGISTRIES	32
ABS1063 THE MANY FACES OF WHIPPLE'S DISEASE	31
ABS0707 DO VARIATIONS OF THE 6-MINUTE WALK TEST ACCURATELY REFLECT CHANGES IN CARDIOPULMONARY COMPLICATIONS DURING THE FOLLOW-UP OF PATIENTS WITH SYSTEMIC SCLEROSIS	31
ABS0665 CORRELATION BETWEEN Ro52 ANTIBODY POSITIVITY AND ELECTROCARDIOGRAPHIC ALTERATIONS IN PATIENTS WITH IDIOPATHIC INFLAMMATORY MYOPATHY	31
ABS0291 CLINICAL AND HEMODYNAMICS OUTCOMES PATIENTS WITH PULMONARY HYPERTENSION AND SYSTEMIC AUTOIMMUNE RHEUMATIC DISEASES	31
ABS0047 MATERNAL AND NEONATAL ANTI-RO52, ANTI-RO60 AND ANTI-LA LEVELS CORRELATE WITH INTERFERON SCORES	31
ABS0015 SKIN MICROBIOME SHOWS DIFFERENCES BETWEEN PATHERGY POSITIVE AND NEGATIVE PATIENTS WITH BEHÇET'S SYNDROME	31
POS0022 Long-Term Outcomes in IgA Vasculitis Nephritis Patients: Insights from the Croatian National Center	30
ABS0110 INTEGRATIVE OMICS REVEALS MOLECULAR SIGNATURES DISTINGUISHING EARLY FROM ESTABLISHED RHEUMATOID ARTHRITIS AND PREDICTING CLINICAL RESPONSE	30
POS1133 Upregulation of pro-survival receptors on antibody-secreting cells is linked to worse disease characteristics across SLE, Scleroderma and Sjögrens disease and offers potential new treatment an	30
POS1337 CLINICAL OUTCOMES OF METHOTREXATE TREATMENT FOR IMMUNE CHECKPOINT INHIBITOR-INDUCED ARTHRITIS IN CANCER PATIENTS: A RETROSPECTIVE LONGITUDINAL PILOT STUDY	30
POS1376 SPUTUM CALPROTECTIN LEVELS DO NOT ADD TO ABILITY OF SPUTUM ANTI-CCP AND RF TO PREDICT FUTURE DEVELOPMENT OF RA IN SERUM ANTI-CCP POSITIVE INDIVIDUALS AT-RISK FOR RA	30
POS0068 POLYGENIC RISK SCORES IMPROVE RISK ASSESSMENT OF CARDIOMETABOLIC COMORBIDITIES IN PATIENTS WITH RHEUMATOID ARTHRITIS	30
POS1118 CLINICAL SIGNIFICANCE OF NON-INFECTIOUS PROCALCITONIN ELEVATION IN THE COURSE OF STILL'S DISEASE	30
POS1206 CLINICAL AND FUNCTIONAL BENEFITS OF EARLY INTRA-ARTICULAR CORTICOSTEROID ADMINISTRATION FOR HIGH-RISK PERSISTENT POST-ARTHROSCOPIC SYNOVITIS	30
OP0081 Anti-Ro/SSA+/RF+ double seropositivity in systemic sclerosis is associated with more severe interstitial lung disease: A study from the EUSTAR database	29
ABS0959 EVALUATION OF MULTIMODAL REHABILITATION AND ITS IMPACT ON COMORBIDITIES AND RISK FACTORS FOR THE TREATMENT OF KNEE PAIN AND IMPROVEMENT OF QUALITY OF LIFE IN EARLY OSTEOARTHRITIS: THE AKAPP ST	29
POS1248 DAMAGE IN SJÖGREN’S DISEASE: INSIGHTS FROM THE GIRRCS SJOGREN’S DISEASE COHORT	29
ABS0350 LONG-TERM CHANGES IN PARAMETERS OF BONE QUALITY IN KIDNEY TRANSPLANT RECIPIENTS TREATED WITH DENOSUMAB	29
POS1402 NEXT GENERATION CAR-NK CELL THERAPY LEVERAGES ALLOIMMUNE DEFENSE TECHNOLOGY TO PERSIST WITHOUT CONDITIONING CHEMOTHERAPY FOR THE TREATMENT OF AUTOIMMUNE DISEASE	29
POS0527 Distinct cardiac phenotypes identified by cardiovascular magnetic resonance in treatment-naïve rheumatoid arthritis: a cluster analysis	29
POS0848 REAL-WORLD CLINICAL CHARACTERISTICS AND PATTERNS OF CARE IN ADULTS WITH SJÖGREN'S DISEASE DIAGNOSED BY RHEUMATOLOGISTS VS NON-RHEUMATOLOGISTS: RETROSPECTIVE ANALYSIS OF US ELECTRONIC HEALTH RE	29
ABS1196-HPR HIGH REPORT OF SIDE-EFFECTS, AND ASSOCIATION OF PATIENTS' AGE WITH TOLERANCE OF SUBCUTANEOUS METHOTREXATE – TELEPHONE SURVEY RESULTS FROM A QUALITY IMPROVEMENT PROJECT	29
ABS0290 LIFE SATISFACTION AND MEDICATION ADHERENCE IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A CROSS-SECTIONAL ANALYSIS OF ELLES COHORT BASELINE DATA	29
ABS0438 ASSOCIATIONS AND RISK FACTORS FOR FREQUENT ORAL ANALGESIC USE IN LOWER LIMB OSTEOARTHRITIS	29
Response to: ‘Correspondence on ‘Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis’’ by Yang et al	28
POS0352 GENETIC DETERMINANTS OF RESPONSE TO ABATACEPT IN PATIENTS WITH IGG4-RELATED DISEASE	28
AB0068 LONG-TERM FOLLOW-UP OF PATIENTS WITH RHEUMATIC DISEASES AND SARS-CoV-2 INFECTION: DATA FROM THE SAR-COVID REGISTRY	28
OP0270 SENSITIVITY OF THE ACR/EULAR CLASSIFICATION CRITERIA IN A MULTICENTER ITALIAN COHORT OF PATIENTS WITH OBSTETRIC ANTIPHOSPHOLIPID SYNDROME (OAPS): IMPLICATIONS FOR CLINICAL PRACTICE	28